Physician profile
Kacee Lambe
NPI 1629883152
$1,567.82
in general payments reported to CMS, 2019-2025
27 companies · $1,568 in 2025
The $1,568 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.83 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $181.17 | 2025 | Erleada, Balversa, Talvey |
| Merck Sharp & Dohme LLC | $175.30 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $145.83 | 2025 | |
| Novartis Pharmaceuticals Corporation | $138.40 | 2025 | |
| Astellas Pharma US INC | $107.93 | 2025 | Vyloy, Xtandi, Padcev |
| Glaxosmithkline, LLC. | $73.57 | 2025 | Ojjaara, Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $69.98 | 2025 | Calquence, Imfinzi |
| Ipsen Biopharmaceuticals, INC | $66.44 | 2025 | Onivyde |
| Eisai INC. | $64.38 | 2025 | |
| Adaptive Biotechnologies Corporation | $57.53 | 2025 | Clonoseq |
| Azurity Pharmaceuticals, INC. | $51.95 | 2025 | Danziten |
| Daiichi Sankyo INC. | $51.25 | 2025 | Enhertu, Datroway |
| Genmab U.S., INC. | $41.62 | 2025 | Epkinly, Tivdak |
| Incyte Corporation | $40.24 | 2025 | Monjuvi, Jakafi, Niktimvo |
| Caris Mpi, INC. | $38.41 | 2025 | Mi Cancer Seek |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $36.14 | 2025 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $29.61 | 2025 | Besremi |
| Abbvie INC. | $27.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.35 | 2025 | Iclusig |
| Aveo Pharmaceuticals, INC. | $22.12 | 2025 | |
| Lilly USA, LLC | $19.46 | 2025 | Retevmo, Verzenio, Jaypirca |
| Pfizer INC. | $19.19 | 2025 | |
| Novocure INC. | $18.25 | 2025 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.99 | 2025 | |
| Celgene Corporation | $17.75 | 2025 | Reblozyl |
| Puma Biotechnology, INC. | $16.11 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.38 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kacee Lambe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.